{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:37:40Z","timestamp":1775277460367,"version":"3.50.1"},"reference-count":82,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>IgA nephropathy (IgAN) represents the most prevalent form of primary glomerulonephritis, and, on a global scale, it ranks among the leading culprits behind end-stage kidney disease (ESKD). Presently, the primary strategy for managing IgAN revolves around optimizing blood pressure and mitigating proteinuria. This is achieved through the utilization of renin\u2013angiotensin system (RAS) inhibitors, namely, angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs). As outlined by the KDIGO guidelines, individuals who continue to show a persistent high risk of progressive ESKD, even with comprehensive supportive care, are candidates for glucocorticoid therapy. Despite these therapies, some patients have a disease refractory to treatment, defined as individuals that present a 24 h urinary protein persistently &gt;1 g after at least two rounds of regular steroids (methylprednisolone or prednisone) and\/or immunosuppressant therapy (e.g., mycophenolate mofetil), or who do not tolerate regular steroids and\/or immunosuppressant therapy. The aim of this Systematic Review is to revise the current literature, using the biomedical database PubMed, to investigate possible therapeutic strategies, including SGLT2 inhibitors, endothelin receptor blockers, targeted-release budesonide, B cell proliferation and differentiation inhibitors, fecal microbiota transplantation, as well as blockade of complement components.<\/jats:p>","DOI":"10.3390\/medicina60020274","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T08:41:43Z","timestamp":1707122503000},"page":"274","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Refractory IgA Nephropathy: A Challenge for Future Nephrologists"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-1999","authenticated-orcid":false,"given":"Vincenzo","family":"Di Leo","sequence":"first","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area-Nephrology, Dialysis and Transplantation Unit, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Annese","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area-Nephrology, Dialysis and Transplantation Unit, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Papadia","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area-Nephrology, Dialysis and Transplantation Unit, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Serena","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area-Nephrology, Dialysis and Transplantation Unit, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marica","family":"Giliberti","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area-Nephrology, Dialysis and Transplantation Unit, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5132-6532","authenticated-orcid":false,"given":"Fabio","family":"Sallustio","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area-Nephrology, Dialysis and Transplantation Unit, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4861-0911","authenticated-orcid":false,"given":"Loreto","family":"Gesualdo","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area-Nephrology, Dialysis and Transplantation Unit, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"IgA nephropathy","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Du, Y., Cheng, T., Liu, C., Zhu, T., Guo, C., Li, S., Rao, X., and Li, J. (2023). IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment. Diagnostics, 13.","DOI":"10.3390\/diagnostics13020303"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/ndt\/gfad146","article-title":"IgA nephropathy in adults\u2014Treatment Standard","volume":"38","author":"Gleeson","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_4","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021). KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int., 100, S1\u2013S276."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.21037\/atm.2018.12.11","article-title":"Random forest can accurately predict the development of end-stage renal disease in immunoglobulin a nephropathy patients","volume":"7","author":"Han","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/0886022X.2021.1936038","article-title":"Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: The first case reports","volume":"43","author":"Zhao","year":"2021","journal-title":"Ren. Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: A randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"ref_9","first-page":"992","article-title":"Intensive Supportive Care plus Immunosuppression in IgA Nephropathy","volume":"374","author":"Floege","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2215\/CJN.0000000000000215","article-title":"Immunosuppression versus Supportive Care on Kidney Outcomes in IgA Nephropathy in the Real-World Setting","volume":"18","author":"Zhao","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.nephro.2018.02.010","article-title":"Treatment of IgA nephropathy: Recent advances and prospects","volume":"14","author":"Coppo","year":"2018","journal-title":"Nephrol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Suzuki, H., and Novak, J. (2022). Special Issue: New Insights into the Pathogenesis and Therapies of IgA Nephropathy. J. Clin. Med., 11.","DOI":"10.3390\/books978-3-0365-5042-8"},{"key":"ref_14","first-page":"29","article-title":"The Treatment of Primary IgA Nephropathy: Change, Change, Change","volume":"83","author":"Caster","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/futurepharmacol3020033","article-title":"The Landscape of IgA Nephropathy Treatment Strategy: A Pharmacological Overview","volume":"3","author":"Annese","year":"2023","journal-title":"Future Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/0148607104028005364","article-title":"The glucose transporter families SGLT and GLUT: Molecular basis of normal and aberrant function","volume":"28","author":"Scheepers","year":"2004","journal-title":"JPEN J. Parenter. Enter. Nutr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MNH.0000000000000152","article-title":"Sodium-glucose cotransport","volume":"24","author":"Poulsen","year":"2015","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1113\/jphysiol.1995.sp020559","article-title":"Mammalian ion-coupled solute transporters","volume":"482","author":"Hediger","year":"1995","journal-title":"J Physiol"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., and Docimo, G. (2022). An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073651"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: Impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"De Nicola, L., Gabbai, F.B., Garofalo, C., Conte, G., and Minutolo, R. (2020). Nephroprotection by SGLT2 Inhibition: Back to the Future?. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072243"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"98720","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.kint.2020.02.041","article-title":"The role of renal hypoxia in the pathogenesis of diabetic kidney disease: A promising target for newer renoprotective agents including SGLT2 inhibitors?","volume":"98","author":"Hesp","year":"2020","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MNH.0000000000000343","article-title":"Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?","volume":"26","author":"Rajasekeran","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"108368","DOI":"10.1016\/j.diabres.2020.108368","article-title":"A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress","volume":"168","author":"Bray","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Salvatore, T., Caturano, A., Galiero, R., Di Martino, A., Albanese, G., Vetrano, E., Sardu, C., Marfella, R., Rinaldi, L., and Sasso, F.C. (2021). Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101356"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.metabol.2018.01.002","article-title":"IL-6 receptor blockade ameliorates diabetic nephropathy via inhibiting inflammasome in mice","volume":"83","author":"Wu","year":"2018","journal-title":"Metab. Clin. Exp."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Panchapakesan, U., Pegg, K., Gross, S., Komala, M.G., Mudaliar, H., Forbes, J., Pollock, C., and Mather, A. (2013). Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054442"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"109506","DOI":"10.1016\/j.cellsig.2019.109506","article-title":"Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition","volume":"68","author":"Das","year":"2020","journal-title":"Cell Signal"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Dou, L., and Jourde-Chiche, N. (2019). Endothelial Toxicity of High Glucose and its by-Products in Diabetic Kidney Disease. Toxins, 11.","DOI":"10.3390\/toxins11100578"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Xu, J., Kitada, M., Ogura, Y., Liu, H., and Koya, D. (2021). Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells. Cells, 10.","DOI":"10.3390\/cells10061457"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"The","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_41","unstructured":"Herrington, W.G., Frankel, A.H., Wonnacott, A., Webb, D., Watt, A., Watson, M., Roberts, J., Staplin, N., Roddick, A., and Riding, A. (2021). UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease, UK Kidney Association."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial","volume":"105","author":"Wimbury","year":"2023","journal-title":"Kidney Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fmed.2020.00092","article-title":"The Role of Immune Modulation in Pathogenesis of IgA Nephropathy","volume":"7","author":"Chang","year":"2020","journal-title":"Front. Med."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Maixnerova, D., El Mehdi, D., Rizk, D.V., Zhang, H., and Tesar, V. (2022). New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102810"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00281-021-00878-5","article-title":"Are there animal models of IgA nephropathy?","volume":"43","author":"Monteiro","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1681\/ASN.2021030372","article-title":"Chimeric Fusion between Clostridium Ramosum IgA Protease and IgG Fc Provides Long-Lasting Clearance of IgA Deposits in Mouse Models of IgA Nephropathy","volume":"33","author":"Xie","year":"2022","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/MAJ.0b013e31824ce676","article-title":"Outcomes of tacrolimus therapy in adults with refractory membranous nephrotic syndrome: A prospective, multicenter clinical trial","volume":"345","author":"Chen","year":"2013","journal-title":"Am. J. Med. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000337175","article-title":"Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy","volume":"35","author":"Zhang","year":"2012","journal-title":"Am. J. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e0610","DOI":"10.1097\/MD.0000000000010610","article-title":"Tacrolimus decreases proteinuria in patients with refractory IgA nephropathy","volume":"97","author":"Hu","year":"2018","journal-title":"Medicine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1189608","DOI":"10.3389\/fphar.2023.1189608","article-title":"Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Song, Y.H., Cai, G.Y., Xiao, Y.F., Wang, Y.P., Yuan, B.S., Xia, Y.Y., Wang, S.Y., Chen, P., Liu, S.W., and Chen, X.M. (2017). Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: A meta-analysis. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0467-z"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3349\/ymj.2013.54.4.973","article-title":"Stepwise treatment using corticosteroids alone and in combination with cyclosporine in korean patients with idiopathic membranous nephropathy","volume":"54","author":"Shin","year":"2013","journal-title":"Yonsei Med. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00281-021-00882-9","article-title":"Complement activation in IgA nephropathy","volume":"43","author":"Cook","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","article-title":"Current treatment of IgA nephropathy","volume":"43","author":"Floege","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ekir.2023.01.041","article-title":"Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study","volume":"8","author":"Rizk","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases","volume":"8","author":"Bradley","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Cheung, C.K., Rajasekaran, A., Barratt, J., and Rizk, D.V. (2021). An Update on the Current State of Management and Clinical Trials for IgA Nephropathy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112493"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.ekir.2023.06.010","article-title":"Challenges in IgA Nephropathy Management: An Era of Complement Inhibition","volume":"8","author":"Tesar","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1175088","DOI":"10.3389\/fneph.2023.1175088","article-title":"IgA nephropathy: A review of existing and emerging therapies","volume":"3","author":"Noor","year":"2023","journal-title":"Front. Nephrol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"823267","DOI":"10.3389\/fmed.2022.823267","article-title":"Gut Microbes in Immunoglobulin A Nephropathy and Their Potential Therapeutic Applications","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Sallustio, F., Curci, C., Di Leo, V., Gallone, A., Pesce, F., and Gesualdo, L. (2019). A New Vision of IgA Nephropathy: The Missing Link. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010189"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MNH.0000000000000565","article-title":"Microbiome modulation to correct uremic toxins and to preserve kidney functions","volume":"29","author":"Caggiano","year":"2020","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Bibbo, S., Settanni, C.R., Porcari, S., Bocchino, E., Ianiro, G., Cammarota, G., and Gasbarrini, A. (2020). Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061757"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Di Leo, V., Gleeson, P.J., Sallustio, F., Bounaix, C., Da Silva, J., Loreto, G., Ben Mkaddem, S., and Monteiro, R.C. (2021). Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model. J. Pers. Med., 11.","DOI":"10.3390\/jpm11040309"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Sallustio, F., Picerno, A., Montenegro, F., Cimmarusti, M.T., Di Leo, V., and Gesualdo, L. (2023). The Human Virome and Its Crosslink with Glomerulonephritis and IgA Nephropathy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043897"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jfma.2018.08.011","article-title":"Fecal microbiota transplantation: Review and update","volume":"118","author":"Wang","year":"2019","journal-title":"J. Formos. Med. Assoc. Taiwan Yi Zhi"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00281-021-00871-y","article-title":"The mucosal immune system and IgA nephropathy","volume":"43","author":"Gesualdo","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"694787","DOI":"10.3389\/fimmu.2021.694787","article-title":"Fecal Microbiota Transplantation Modulates Renal Phenotype in the Humanized Mouse Model of IgA Nephropathy","volume":"12","author":"Lauriero","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"914250","DOI":"10.3389\/fmed.2022.914250","article-title":"Fecal Capsule as a Therapeutic Strategy in IgA Nephropathy: A Brief Report","volume":"9","author":"Zhi","year":"2022","journal-title":"Front. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/43219","article-title":"Structure and function of a new STAT-induced STAT inhibitor","volume":"387","author":"Naka","year":"1997","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2249.1998.00612.x","article-title":"IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB\/W F1 mice","volume":"112","author":"Mihara","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","article-title":"Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma","volume":"180","author":"Kitaba","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1042\/CS20150711","article-title":"Aberrantly methylated DNA regions lead to low activation of CD4+ T-cells in IgA nephropathy","volume":"130","author":"Sallustio","year":"2016","journal-title":"Clin. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejim.2023.07.045","article-title":"Elevated levels of IL-6 in IgA nephropathy patients are induced by an epigenetically driven mechanism modulated by viral and bacterial RNA","volume":"118","author":"Sallustio","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"118436","DOI":"10.1016\/j.lfs.2020.118436","article-title":"PKR inhibitor imoxin prevents hypertension, endothelial dysfunction and cardiac and vascular remodelling in L-NAME-treated rats","volume":"262","author":"Kalra","year":"2020","journal-title":"Life Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/fcp.12261","article-title":"Double-stranded RNA-dependent protein kinase signalling and paradigms of cardiometabolic syndrome","volume":"31","author":"Kalra","year":"2017","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and treatment of glomerular diseases (part 1): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Floege","year":"2019","journal-title":"Kidney Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11906-020-1033-9","article-title":"Preeclampsia and Glomerulonephritis: A Bidirectional Association","volume":"22","author":"Capaccio","year":"2020","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1742-1241.2009.02038.x","article-title":"ACEI\/ARB therapy for IgA nephropathy: A meta analysis of randomised controlled trials","volume":"63","author":"Cheng","year":"2009","journal-title":"Int. J. Clin. Pract."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/2\/274\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:55:01Z","timestamp":1760104501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/2\/274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":82,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["medicina60020274"],"URL":"https:\/\/doi.org\/10.3390\/medicina60020274","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]}}}